Hurley Capital’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Hurley Capital's CRSP Position: Q3 2026 in Review
Hurley Capital held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 80 shares worth $4.43K. The position accounts for ﹤0.01% of the portfolio, ranked #453.
Hurley Capital first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.18K in Q3 2025. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Hurley Capital held 80 shares of CRISPR Therapeutics worth $4.43K as of Q3 2026.
- Hurley Capital left its CRISPR Therapeutics share count unchanged in Q3 2026.
- CRISPR Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q3 2026, its #453 holding.
- Hurley Capital first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
- Hurley Capital's CRISPR Therapeutics position peaked at $5.18K in Q3 2025.
- 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.